We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
10 own
11 watching
Current Price
$0.75
$0.01
(0.74%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
112.08M
52-Week High
3.33000
52-Week Low
0.67000
Average Volume
3.33M
Dividend Yield
--
P/E Ratio
--
Market Capitalization112.08M52-Week High3.3300052-Week Low0.67000Average Volume3.33MDividend Yield--P/E Ratio--What does the Stockal+Disclaimer.pdf do?
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
1 year ago
EMERYVILLE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced that the Compensation Committee of the companys Board of Directors granted one employee nonqualified...
Globe Newswire
1 year ago
Conference call to begin at 4:30pm ET on March 9EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the worlds most potent vaccines, today announced it will report its fourth quarter and full year 2022 ...
Globe Newswire
1 year ago
Matthew Hawryluk, Ph.D.
POAI Board of Directors
EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the companys ...
Globe Newswire
1 year ago
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months median not yet reached -- -- Patients who achieve a molecular response include those with liver ...
Globe Newswire
1 year ago
EMERYVILLE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced that the companys Board of Directors has granted eight employees nonqualified stock options to ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$0.75
$0.01
(0.74%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.